Brian Philippe Tinmouth - Dec 23, 2021 Form 3 Insider Report for PARDES BIOSCIENCES, INC. (PRDS)

Role
Chief Business & Strategy Ofcr
Signature
/s/ Elizabeth Lacy, attorney-in-fact
Stock symbol
PRDS
Transactions as of
Dec 23, 2021
Transactions value $
$0
Form type
3
Date filed
12/27/2021, 04:13 PM
Previous filing
Jun 21, 2021
Next filing
Jun 22, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRDS Stock Option (Right to Buy) Dec 23, 2021 Common Stock 28.2K $4.94 Direct F1
holding PRDS Stock Option (Right to Buy) Dec 23, 2021 Common Stock 422K $8.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 50% of the shares subject to such option vest and become exercisable on June 23, 2022, and 1/24th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on the 23rd day of each month thereafter, subject to a continued service relationship.
F2 1/4th of the shares subject to such option vest and become exercisable on November 22, 2022, and 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on the 22nd day of each month thereafter, subject to a continued service relationship.

Remarks:

Exhibit 24 - Power of Attorney Effective immediately following the effective time of the merger pursuant to that certain Agreement and Plan of Merger dated as of June 29, 2021, as amended, by and among Pardes Biosciences Sub, Inc. (f/k/a Pardes Biosciences, Inc.), Issuer (f/k/a FS Development Corp. II), and certain other parties thereto, the reporting person became an officer of the Issuer.